Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738408 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL4430217 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL13598781 | 1.00 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BPRMT5 | |
| SCHEMBL14440600 | 0.92 | ADORA2A (0.47) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL1740552 | 0.89 | ADORA2A (0.43) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL18661709 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL18661710 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL12219557 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL12194659 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3PRMT5WDR77 | |
| SCHEMBL16311924 | 0.87 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629328-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7432248-B2 | Nucleoside derivatives for treating Hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7414031-B2 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414031-B2 | 5-nitro-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NSUN2 | ADORA2A 45/4885ADORA3 55/4885ADORA1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.